SRSD107
Chronic Coronary and/or Peripheral Arterial Disease
Phase 2Active
Key Facts
Indication
Chronic Coronary and/or Peripheral Arterial Disease
Phase
Phase 2
Status
Active
Company
About Sirius Therapeutics
Sirius Therapeutics is an innovative, privately-held biotech advancing a pipeline of siRNA therapies targeting major chronic diseases, with lead programs in Phase 2 and Phase 1/2a trials. The company has established a strong operational footprint in both the US and China, securing funding from top-tier investors like OrbiMed and forging a strategic collaboration with CRISPR Therapeutics. Its strategy is built on three 'mega-blockbuster' franchises in cardiovascular and metabolic diseases, supported by its proprietary PEPR siRNA technology platform.
View full company profile